In 2006 Covance acquired the assets of Signet™ Laboratories, located in Dedham, MA. Covance is pleased to offer the outstanding line of Signet antibodies, detection kits, and immunological reagents, including industry leading monoclonal antibodies to beta amyloid and other vital targets for Alzheimer's, Parkinson's, and prion disease research.
Signet™'s line of beta amyloid products, highlighted by gold standards 6E10 and 4G8, includes the most comprehensive list of antibodies available for beta amyloid and APP processing. High quality products are also available for Tau, α-synuclein, parkin, DJ-1, and many other targets.
Signet™ was created in 1989 as a commercial spinout of Johnson & Johnson's Cambridge Research Laboratories, Inc. (CRL, Cambridge, MA). The Company was founded to continue the mission originally established at CRL-the early detection and recurrence monitoring of patients with cancer and infectious disease. Signet has developed patented technology for diagnosis and recurrence monitoring and for risk assessment of asymptomatic patients in these areas. For more than a decade, the Company has aggressively maintained licensing and development programs, which are responsible for its broad patent and intellectual estate.